BioVigilant Systems, Inc, inventors of Instantaneous Microbial Detection™, announced today it has filed Type V Drug Master Files (DMFs) for its IMD-A® 300 series of rapid biologic detection systems for real-time environmental air monitoring in pharmaceutical manufacturing environments.
BioVigilant Systems, Inc., (www.biovigilant.com), inventors of Instantaneous Microbial Detection™, today announced the introduction of its next-generation IMD-A ® family of rapid biologic detection systems for real-time environmental air monitoring in pharmaceutical manufacturing environments.
The new liquid ready-to-use fructosamine assay from Randox is now available. The new formulation makes the assay easier to use requiring no offline preparation; based on an enzymatic method it also offers superior performance in terms of specificity and reliability compared to traditional NBT based methods.
Gerteis dedication to understanding their processes and improving dry granulation technology for 25 years leads to their most successful year to date.
Meet Biovian at the ICSE-BioPh International Contract Services Expo 25 - 27 October 2011, Frankfurt, Germany
Meet Biovian at the BioEurope 2011 partnering conference, which will be held 31 October - 2 November 2011 in Duesseldorf, Germany.
Meet Biovian at the 19th BioPartnering Europe 2011 conference, which will be held 10-11 October 2011 in London.
Exploristics, the innovative data analysis group, published a paper describing the practices and opportunities for study design and data analysis in Pharmacogenetics (PGx).
Kinapse is pleased to announce its support of Talentmark’s 40th Anniversary celebrations at a ‘Futureceuticals’ event being held today at the Royal College of Surgeons in London.
GoIndustry DoveBid, global leaders in surplus asset management, continues to provide buyers with the leading industry-specific equipment marketplaces. These marketplaces allow buyers to acquire quality used biotech and pharmaceutical equipment to meet their requirements. GoIndustry DoveBid will be auctioning more than 2,500 lots in the month of September on behalf of Pfizer, Exelixis, Bristol-Myers Squibb and several other top global biopharmaceutical companies. These assets are surplus to their ongoing operations and will be immediately available for purchase through the BioPharma Exchange program.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.